- Home
- IMXI vs PHAR Comparison
IMXI vs PHAR Comparison
Compare IMXI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMXI | PHAR |
|---|---|---|
| Founded | 1994 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.2M | 1.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | IMXI | PHAR |
|---|---|---|
| Price | $15.39 | $18.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $16.67 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 212.3K | 24.5K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.29 | 0.00 |
| Revenue | ★ $625,123,000.00 | $362,274,000.00 |
| Revenue This Year | N/A | $25.19 |
| Revenue Next Year | $0.95 | $4.47 |
| P/E Ratio | ★ $11.96 | $3,041.40 |
| Revenue Growth | N/A | ★ 26.78 |
| 52 Week Low | $8.58 | $7.50 |
| 52 Week High | $21.41 | $18.30 |
Technical Indicators
Market Signals| Indicator | IMXI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 62.13 | 58.10 |
| Support Level | $15.32 | $16.98 |
| Resistance Level | $15.42 | $17.00 |
| Average True Range (ATR) | 0.06 | 0.69 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 36.21 | 82.04 |
Price Performance
Historical ComparisonAbout IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.